SCHEMBL4257927

SCHEMBL4257927

CC1=C(C#N)S(=O)(=O)c2cc(Cl)ccc2N1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC8 Q09428 3/20 0.49
KCNJ11 Q14654 3/20 0.49
ALDH1A1 P00352 2/20 0.49
CYP1A2 P05177 2/20 0.49
LMNA P02545 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
THRB P10828 1/20 0.49
TSHR P16473 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CA12 O43570 2/20 0.44
CA2 P00918 2/20 0.44
CA4 P22748 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA1 P00915 1/20 0.44
KDM4E B2RXH2 3/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CHEK1 O14757 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7932571 0.90 ABCC8 (0.40) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
SCHEMBL7929286 0.83 ABCC8 (0.45) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
SCHEMBL4256305 0.82 CA12 (0.44) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
SCHEMBL7922807 0.82 ABCC8 (0.43) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
SCHEMBL4266841 0.80 KDM4E (0.56) ABCC8KCNJ11ALDH1A1CA12CA2
SCHEMBL7931865 0.80 ABCC8 (0.41) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
SCHEMBL4264227 0.77 CA1 (0.35) CA12CA2CA4CA7CA9
SCHEMBL4257284 0.73 MAPT (0.40) ALDH1A1CA2CA1HPGDHSD17B10
SCHEMBL11467613 0.68 CA12 (0.42) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
Diazoxide SCHEMBL41255 0.66 ABCC8 (1.00) ABCC8KCNJ11ALDH1A1CYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6232310-B1 ANTIDIABETIC AGENTS NOVO NORDISK A/S (DK) 2001-05-15 US claimed
US-20090012067-A1 Modulation of Hypothalamic Atp-Sensitive Potassium Channels ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. 2009-01-08 US disclosed
US-20090012067-A1 Modulation of Hypothalamic Atp-Sensitive Potassium Channels ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. 2009-01-08 US disclosed
US-20090012067-A1 Modulation of Hypothalamic Atp-Sensitive Potassium Channels ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. 2009-01-08 US disclosed
US-20070026079-A1 Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels DARA BIOSCIENCES, INC. 2007-02-01 US disclosed
US-20070026079-A1 Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels DARA BIOSCIENCES, INC. 2007-02-01 US disclosed
US-20070026079-A1 Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels DARA BIOSCIENCES, INC. 2007-02-01 US disclosed
US-6232310-B1 ANTIDIABETIC AGENTS NOVO NORDISK A/S (DK) 2001-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012067-A1 Modulation of Hypothalamic Atp-Sensitive Potassium Channels PYGB, PC, KCNN3 ABCC8 415/4885KCNJ11 18/4885ALDH1A1 1698/4885
US-20070026079-A1 Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels PC, LIPE, ATP5ME ABCC8 605/4885KCNJ11 24/4885ALDH1A1 2055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.